Phase 2 Study of Safety, Tolerability and Efficacy of Pirfenidone in Patients With Rheumatoid Arthritis Interstitial Lung Disease

Trial Profile

Phase 2 Study of Safety, Tolerability and Efficacy of Pirfenidone in Patients With Rheumatoid Arthritis Interstitial Lung Disease

Recruiting
Phase of Trial: Phase II

Latest Information Update: 17 Jun 2017

At a glance

  • Drugs Pirfenidone (Primary)
  • Indications Interstitial lung diseases
  • Focus Therapeutic Use
  • Most Recent Events

    • 13 Jun 2017 Status changed from not yet recruiting to recruiting.
    • 10 Jun 2017 Biomarkers information updated
    • 17 Aug 2016 Planned primary completion date changed from 1 Oct 2020 to 1 Jan 2021.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top